

General Information:

Plan Report ID Number: 20211216LIL

Developer Name: Lille Group, Inc

Product Name(s): eScribeHOST

Version Number(s): 7

Certified Health IT

Product List (CHPL) ID(s): 15.02.05.3058.LILG.01.01.1.220214 (current),
15.02.02.3058.A109.01.00.1.191230 (previous)

Developer Real World Testing Page URL: <https://www.escribe.com/transparency-esh.html>

Summary of Testing Methods:

Real World Testing was completed by third party testers per the RWT plans established by Lille Group, Inc. and approved by ACB. Testers were given arbitrary time frames to access the app and complete testing in accordance with an on-going testing approach. Testers were given two sets of log on credentials, one with a complete set of permissions to access all required patient data for testing, one without complete permissions to demonstrate inability to access protected information (170.315(b,e)). In addition, testers were given a set of instructions outlining all actions required to test each criterion completely.

Testers reported all results and findings along with screenshots and copies of downloaded files to the third party testing administrator for review and compilation of results. The testing administrator then converted tester's results to rate of success metric in line with the RWT plans.

Summary of Key Findings:

As described in this report, all testing was conducted successfully with zero nonconforming results found. All testing was completed well within the acceptable time frame of 24 working hours outlined in the RWT plans.

The speed at which testing was completed, an average of 20 minutes per test, demonstrates an on-going ease of use of the application and ease of accessing, editing and downloading all required data.

Each criterion was tested by 3 different testers evaluating 3 patient data sets each, as outlined in the RWT plans. Using multiple third party testers to evaluate each criterion demonstrates continuity of results and real-world interoperability.

No non-conformities were discovered during testing. No deviations from the original testing plan were present. All results are within expected range of success.

Standards Updates via SVAP and/or USCDI:

No standards updated.

Care Setting(s):

| Care Setting | Justification |
|-------------------|--|
| Cardiology Office | EscribeHost is marketed to cardiology practices and has been tested in accordance with our cardiology clientele. The care setting where patient information should be accessed, added, changed and exchanged is in the office among only professionals with appropriate permissions. |

Metrics and Outcomes:

All tests are reported in the metric of rate of success. Rate of success is reported as the percentage of successful attempts to perform actions defined above out of total attempts to perform actions defined in RWT plans. All attempts are defined as successful if performed completely and in accordance with all specifications within a reasonable time, defined as one day (24 hours), or one working day (24 hours discounting weekends and holidays) for criteria relying on outside parties who do not operate on a constant basis (pharmacies, etc).

No additional software has been relied upon in the testing process to obtain results.

| Test | Metric | Associated Criterion | Outcome | Challenges Encountered |
|---|-----------------|----------------------------------|---------|------------------------|
| Patient information can be accessed and edited on demand with appropriate permissions | Rate of Success | 170.315(b)(6), 170.315 (b)(2) | 100% | |
| Patient interventions can be accessed and edited on demand with appropriate permissions | Rate of Success | 170.315(b)(2) | 100% | |
| Patient problems can be accessed and edited on demand with appropriate permissions | Rate of Success | 170.315(b)(2) | 100% | |
| Patient medications can be accessed on demand with appropriate permissions | Rate of Success | 170.315(b)(2) | 100% | |

| | | | | |
|--|-----------------|---------------------------------|------|------------------|
| Patient allergies can be accessed on demand with appropriate permissions | Rate of Success | 170.315(b)(2) | 100% | |
| Confirmed presence of all required fields/data in patient transition of care documents | Rate of Success | 170.315(b)(1) | 100% | |
| System responds to all required prescription requests | Rate of Success | 170.315(b)(3) | 100% | |
| Exported CQMs contain all required fields | Rate of Success | 170.315(c)(1) | 100% | |
| CQMs can be exported on demand at any time with appropriate permissions | Rate of Success | 170.315(c)(1) | 100% | |
| Lab Reports can be downloaded in human readable format on demand by users with appropriate permissions | Rate of Success | 170.315(e)(1) | 100% | Where applicable |
| Imaging Reports can be downloaded in human readable format on demand by users with appropriate permissions | Rate of Success | 170.315(e)(1) | 100% | Where applicable |
| Reports contain all required data | Rate of Success | 170.315(e)(1) | 100% | |
| Lab and Imaging Reports cannot be accessed by users without appropriate permissions | Rate of Success | 170.315(e)(1) | 100% | |
| Information can be accessed by a user with appropriate permissions via unique patient ID | Rate of Success | 170.315(g)(7), 170.315(g)(9) | 100% | |
| API patient data is complete with all required fields | Rate of Success | 170.315(g)(8) | 100% | |

Key Milestones:

All Milestones are within the care setting of Cardiology Offices.

| Milestone | Date/Timeframe |
|--|---------------------------------------|
| ACB approves RWT plans | January 2022 |
| Lille Group, Inc. writes testing scripts | January 2022 |
| Testing is performed | February 3, 2022 - November 20, 2022 |
| Results are recorded and supplied to testing authority | February 3, 2022 - November 20, 2022 |
| Results are assessed and compiled | December 5, 2022 - December 18, 2022 |
| Report template is created | December 18, 2022 |
| Report is completed with results and evaluations | December 18, 2022 - December 21, 2022 |
| Report submitted for ACB review | December 2022 |
| Report revised per ACB feedback | January 25, 2023 |
| Report revised per ACB feedback | February 13, 2023 |
| Report posted to Lille Group, Inc. website | February, 2023 |

Evaluation of Results:

Real World Testing (RWT) for EscribeHOST was conducted by three testers familiar with the application in Q4 2022. Explanation of the RWT process, instructions to third party testers on how to access the test environment as well as specific instructions on how to submit results were included in an introductory email and testers were asked to proceed on their own schedule using arbitrary times and dates, record time spent on each test and to alert the test administrator when complete. Results were compiled by the test administrator and saved for later review. These results were converted by the test administrator to rate of success in accordance with the RWT plans.

All third party testers were clear on expectations and testing time was well within established expectations set previously by internal testers, approximately 20 min per set of three patients per test for less than 1 hour of total testing time per testing session, excluding planned downtime per the RWT plan.

Testing results were clear and demonstrated each tester's facility with the EscribeHOST application as well as the applications functionality relative to generating desired results.

Results were expected in the 80-100% range for rate of success, and all results fell within this range.

Testing successfully demonstrated real world usability on an on-going basis of EscribeHost in reference to all certified criteria.